NYSE •
Healthcare •
Biotechnology •
Quote as of 08/18/2026 13:08
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization7.28 mln
Float2.14 mln
Earnings Date08/27/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-3.95
Highly reliable
Relative Strength
91
/ 100
Top performer
Debt / Equity
0.01
Debt-free
ROE
-194
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Can-Fite BioPharma is an Israeli drug development company focused on creating oral treatments for cancer, liver disease, and erectile dysfunction. Its two most advanced medicines, Piclidenoson and Namodenoson, are being tested in late-stage clinical trials for conditions including psoriasis, liver cancer, and pancreatic cancer. The company also partners with other firms to expand the reach of its treatments and explore cannabis-based therapies for cancer and inflammatory conditions. Founded in 1994 and based in Ramat Gan, Israel, Can-Fite also offers a diagnostic blood test to help predict how patients may respond to its drugs.
